Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 178 publications
Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 26, 2026
Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement.
Journal: Cancer
Published: April 19, 2026
Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).
Journal: The oncologist
Published: January 27, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).
Journal: The Lancet. Oncology
Published: December 22, 2025
[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Journal: Lancet (London, England)
Published: December 04, 2025
Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
Journal: Endocrine-related cancer
Published: November 17, 2025
Emerging Diagnostics and Therapies in Neuroendocrine Neoplasms: A Critical Review.
Journal: Cancers
Published: October 15, 2025
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
Journal: Endocrine pathology
Published: September 13, 2025
Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 03, 2025
Clinical characteristics of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
Journal: ERJ open research
Published: June 23, 2025
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients?
Journal: The Lancet regional health. Europe
Published: June 14, 2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Journal: JCO oncology practice
Published: May 09, 2025
Last Updated: 09/26/2026